A Review on the Therapeutic Management of COVID-19 Associated with Thrombotic Events and Coagulopathies
R. Vigneswaran
Department of Pharmaceutics, Arulmigu Kalasalingam College of Pharmacy, Anand Nagar, Krishnan Koil – 626126, India.
S. R. Senthil Kumar *
Department of Pharmaceutics, Arulmigu Kalasalingam College of Pharmacy, Anand Nagar, Krishnan Koil – 626126, India.
T. Venkatachalam
Department of Pharmaceutical Chemistry, JKKMMRF’s- Annai JKK Sampoorani Ammal College of Pharmacy, B. Komarapalayam, Namakkal - 638 183, India.
P. Kalaiselvi
Department of Pharmaceutical Chemistry, JKKMMRF’s- Annai JKK Sampoorani Ammal College of Pharmacy, B. Komarapalayam, Namakkal - 638 183, India.
K. Sattanathan
Department of Pharmaceutical Chemistry, Paavai College of Pharmacy and Research, R. Puliyampatti, Namakkal- 637 018, India.
R. Rajaguru
Department of Pharmacy, Annamalai University, Chidambaram, India.
N. Srinivasan
Department of Pharmacy, Annamalai University, Chidambaram, India.
*Author to whom correspondence should be addressed.
Abstract
Severe acute respiratory syndrome coronavirus two (SARS-CoV-2) is answerable for the coronavirus illness in 2019 (COVID-19) that chop-chop evolved from a virus in metropolis, Varied coagulopathies are rumored in association with COVID-19, together with disseminated intavasular action (DIC) sepsis-induced coagulopathy (SIC), native microthrombi, blood vessel occulation (VTE), blood vessels thrombotic complications and thrombo inflammation. There’s a overplus of publications and conflicting information on hematologic and astringent derangements in COVID-19 with some information suggesting the link to illness progress, severity and/or mortality. There is also growing evidence of potentially usefull clinical biomarkers to predict COVID-19 progression and illness outcomes of these, a link between blood disease and COVID-19 severity or mortality was instructed. During this opinion report, we have a tendency to examine the revealed proof of hematological and astringent laboratory derangements in COVID-19 and also the reticular SARS-CoV-2 evoked inflammation, with a focused discussion on blood platelet count alterations.
Keywords: Thrombotic actions, coagulopathies, COVID-19, SARS-CoV-2, blood platelet count